Deutsche Bank
BBIO icon

Deutsche Bank’s BridgeBio Pharma BBIO Stock Holding History

Deutsche Bank’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.7M Sell
277,466
-19,217
-6% -$1.35M 0.01% 850
2026
Q1 		$22M Sell
296,683
-84,380
-22% -$6.12M 0.01% 824
2025
Q4 		$29.1M Sell
381,063
-45,237
-11% -$2.97M 0.01% 784
2025
Q3 		$22.1M Sell
426,300
-19,226
-4% -$938K 0.01% 820
2025
Q2 		$19.2M Buy
445,526
+90,433
+25% +$3.29M 0.01% 847
2025
Q1 		$12.3M Buy
355,093
+78,248
+28% +$2.64M ﹤0.01% 955
2024
Q4 		$7.6M Sell
276,845
-20,236
-7% -$523K ﹤0.01% 1135
2024
Q3 		$7.56M Buy
297,081
+18,850
+7% +$495K ﹤0.01% 1114
2024
Q2 		$7.05M Sell
278,231
-51,978
-16% -$1.42M ﹤0.01% 1111
2024
Q1 		$10.2M Buy
330,209
+84,156
+34% +$2.86M ﹤0.01% 1010
2023
Q4 		$9.93M Buy
246,053
+44,777
+22% +$1.34M 0.01% 999
2023
Q3 		$5.31M Sell
201,276
-71,001
-26% -$2.01M ﹤0.01% 1016
2023
Q2 		$4.68M Sell
272,277
-115,809
-30% -$1.74M ﹤0.01% 1265
2023
Q1 		$6.43M Buy
388,086
+101,938
+36% +$1.19M ﹤0.01% 1126
2022
Q4 		$2.18M Buy
286,148
+96,114
+51% +$920K ﹤0.01% 1612
2022
Q3 		$1.89M Buy
190,034
+82,139
+76% +$853K ﹤0.01% 1652
2022
Q2 		$979K Buy
107,895
+42,729
+66% +$357K ﹤0.01% 2198
2022
Q1 		$662K Sell
65,166
-4,423
-6% -$45.4K ﹤0.01% 2586
2021
Q4 		$1.16M Sell
69,589
-14,722
-17% -$623K ﹤0.01% 2342
2021
Q3 		$3.95M Sell
84,311
-242,751
-74% -$13M ﹤0.01% 1647
2021
Q2 		$19.9M Sell
327,062
-199,698
-38% -$11.4M 0.01% 900
2021
Q1 		$32.4M Buy
526,760
+472,390
+869% +$30.9M 0.02% 728
2020
Q4 		$3.87M Buy
54,370
+14,585
+37% +$704K ﹤0.01% 1498
2020
Q3 		$1.49M Sell
39,785
-2,171
-5% -$68.3K ﹤0.01% 1925
2020
Q2 		$1.37M Buy
41,956
+15,903
+61% +$484K ﹤0.01% 2024
2020
Q1 		$755K Buy
26,053
+17,952
+222% +$557K ﹤0.01% 2250
2019
Q4 		$283K Buy
8,101
+1,574
+24% +$43.6K ﹤0.01% 3026
2019
Q3 		$138K Buy
+6,527
New +$181K ﹤0.01% 3391

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Deutsche Bank's BBIO Position: Q2 2026 in Review

Deutsche Bank reduced its BridgeBio Pharma (BBIO) stake by 6.5% in Q2 2026, selling an estimated $1.35M and leaving 277,466 shares worth $20.7M. The position accounts for 0.01% of the portfolio, ranked #850.

Deutsche Bank first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $32.4M in Q1 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Deutsche Bank held 277,466 shares of BridgeBio Pharma worth $20.7M as of Q2 2026.
  • Deutsche Bank sold 19,217 BridgeBio Pharma shares in Q2 2026, an estimated $1.35M.
  • BridgeBio Pharma made up 0.01% of Deutsche Bank's portfolio in Q2 2026, its #850 holding.
  • Deutsche Bank first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • Deutsche Bank's BridgeBio Pharma position peaked at $32.4M in Q1 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.